Aprea Therapeutics, Inc. Form 8-K Summary
Business context and reporting period
Aprea Therapeutics, Inc. filed a Form 8-K dated January 30, 2023, under Item 5.02 to report a change in its senior financial leadership. The company is a Delaware biopharmaceutical issuer whose common stock trades on Nasdaq under the symbol APRE.
Key financial and operating information
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other period-end financial metrics. It is focused on executive appointments and separation arrangements.
- John Hamill became Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective January 30, 2023.
- Mr. Hamill’s annual base salary is $420,000, with a target annual bonus opportunity equal to 40% of base salary.
- He will receive a $50,000 sign-on bonus payable in March 2024, subject to continued employment through the payment date.
- The company agreed to grant Mr. Hamill an option for 539,758 common shares and 269,879 restricted stock units.
Material changes versus the prior comparable period
- Mr. Hamill replaced Scott Coiante as the company’s senior financial officer effective January 30, 2023.
- Mr. Coiante ceased to be an officer, executive, or agent on the Transition Date but remained with the company through March 31, 2023, to support the leadership transition.
- Mr. Coiante continued to receive his existing base salary and medical benefits through March 31, 2023, subject to performing transition duties.
- Following his departure, Mr. Coiante is entitled, subject to a general release, to 12 months of annual base salary and specified health-insurance-related payments.
Compensation, outlook, risks, and unusual items
- Mr. Hamill’s stock option has a ten-year term, an exercise price equal to the company’s closing stock price on January 30, 2023, and four-year vesting, with 25% vesting after one year and the remainder ratably over the following 36 months.
- The RSUs vest over three years, with one-third vesting on each annual anniversary of the grant date.
- If Mr. Hamill is terminated without cause or resigns for good reason, he may receive nine months of base salary, a prorated target bonus for the termination year, and specified COBRA-related payments, subject to execution of a release.
- Following a change of control, a qualifying termination would result in immediate vesting of all unvested equity awards and could extend certain benefits to 12 months.
- The filing states that the executive employment agreement and separation agreement descriptions are incomplete and that the full agreements will be filed in a subsequent Exchange Act filing.
- No financial guidance or broader business outlook is provided.
Important facts for investors to verify
- Review the subsequent filing containing Mr. Hamill’s complete employment agreement.
- Review the subsequent filing containing Mr. Coiante’s complete separation agreement.
- Verify the option exercise price based on the company’s January 30, 2023 closing share price.
- Assess the share dilution and compensation expense associated with the option and RSU awards.
- Consult subsequent financial statements for the company’s cash position, liquidity, operating losses, and financing needs; these amounts are not provided in this 8-K.